0 Items
Select Page

Giardia

Giardia lamblia is an anaerobic, flagellated eukaryotic protozoan and member of the Hexamitidae family of protozoa. Giardia lamblia infects and colonises the small intestine of humans and mammals, causing a globally-common diarrheal disease, known as giardiasis.

The Native Antigen Company offers Giardia monoclonal antibodies for use in immunoassay development.

Giardia Background

Giardia lamblia exists in two forms, as a dormant cyst that infects the small intestine and as a trophozoite – a vegetative form that excysts from the cyst. Trophozoites replicate within the intestine causing the symptoms associated with giardiasis. Both cysts and trophozoites are present in contaminated faeces, but trophozoites do not survive for long periods in the environment. G. lamblia cysts are found in soil and water, and on surfaces contaminated by faeces from an infected individual. Giardiasis infection in humans occurs by transmission of dormant G. lamblia cysts via the faecal oral route or through ingestion of contaminated food and water (CDC).

Giardia Antibodies

Our Giardia-specific antibodies are specific to the trophozoite protein of Giardia lamblia. Our Giardia antibodies do not cross react with Campylobacter spp., Clostridium difficile, Cryptosporidium parvum, Entamoeba histolytica, Escherichia coli, Helicobacter pylori, Listeria monocytogenes, Salmonella spp., Shigella spp. or Staphylococcus aureus.

We also have two monoclonal antibodies available, which may be used as pairs in immunoassay development.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Overcoming Zika-Dengue cross-reactivity: the highly specific immunoassays your lab needs

In the global battle against Zika virus, serological cross-reactivity with Dengue is a major challenge for academics, epidemiologists and pharmaceutical companies alike. Novel immunoassays can now overcome this problem and could prove a real game-changer in Zika...

The Right Tools for Rubella

Rubella remains a significant pathogen worldwide, with 100,000 cases of congenital rubella syndrome estimated to occur every year. Vaccines to rubella are highly safe and have effectively eliminated endemic infection in many developed countries, yet inadequate...

Visualising viral infection with immunofluorescence microscopy

Following the latest immunofluoresence data for our Zika and Dengue antibodies, we’ve invited VRS to write a short blog one of their areas of expertise: The applications of immunofluorescence microscopy in studying viruses.   A lot of what we know about biology...

Challenges to Effective Yellow Fever Diagnostics

Yellow fever is a haemorrhagic viral disease, transmitted by infected mosquitos in Africa and South America. While an effective vaccine is available, inadequate vaccination of endemic areas has made diagnostics a necessity to controlling ongoing outbreaks. However,...

Five Methods You Can Use to Overcome Zika-Dengue Cross-Reactivity

Cross-reactivity between the Zika and Dengue viruses in serological assays is one of the biggest challenges faced by the epidemiologists, academics and pharmaceutical companies trying to control the Zika epidemic, as it brings the quality and reliability of diagnostic...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

12 + 8 =

Live Customer Feedback